The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B (Journal article)
Kaba, S. E./ DeMonte, F./ Bruner, J. M./ Kyritsis, A. P./ Jaeckle, K. A./ Levin, V./ Yung, W. K.
OBJECTIVE: Recurrent malignant meningiomas and unresectable meningiomas represent a great therapeutic challenge after the failure of radiation therapy. No effective chemotherapy has been found. We report the preliminary results of the treatment of patients with recurrent unresectable or malignant meningiomas with recombinant interferon alpha-2B (IFN-alpha-2B). METHOD: Each of six patients with either a recurrent malignant meningioma or an unresectable meningioma was treated with IFN-alpha, administered subcutaneously at a dosage of 4 mU/m2 per day, 5 days per week. Two of the six meningiomas were regular, one was atypical, and three were malignant. RESULTS: Five of six patients exhibited positive response to treatment; with stabilization of the size of the tumor in four patients and slight regression in one. The responses observed lasted from 6 to 14 months. The toxicity associated with prolonged use of IFN-alpha was mild and well tolerated. CONCLUSION: These results suggest that IFN-alpha is effective in the treatment of recurrent malignant meningiomas.
|Institution and School/Department of submitter:||Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής|
|Keywords:||Adult,Aged,Brain/pathology,Dose-Response Relationship, Drug,Drug Administration Schedule,Female,Humans,Injections, Subcutaneous,Interferon-alpha/*administration & dosage/adverse effects,Magnetic Resonance Imaging,Male,Meningeal Neoplasms/pathology/*therapy,Meningioma/pathology/*therapy,Middle Aged,Neoplasm Recurrence, Local/pathology/*therapy,Neoplasm Staging,Recombinant Proteins,Treatment Outcome|
|Appears in Collections:||Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)|
Files in This Item:
There are no files associated with this item.
Please use this identifier to cite or link to this item:This item is a favorite for 0 people.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.